• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: John Thomas Freeburg was granted 50,000 units of Common Stock, increasing direct ownership by 2,500% to 52,000 units

    3/12/21 4:57:58 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care
    Get the next $IDXG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Freeburg Thomas John

    (Last) (First) (Middle)
    INTERPACE BIOSCIENCES, INC
    300 INTERPACE PARKWAY

    (Street)
    PARSIPPANY NJ 07054

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INTERPACE BIOSCIENCES, INC. [ IDGX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/10/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/10/2021 A 50,000(1) A (2) 52,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $6 03/10/2021 A 50,000 (3) 03/10/2031 Common Stock 50,000 $0 50,000 D
    Explanation of Responses:
    1. The restricted stock units vest annually, in equal installments, over a three-year period, commencing on March 10, 2021.
    2. Each restricted stock unit represents the contingent right to receive one share of common stock of the Issuer.
    3. The stock options vest and become exercisable over a three-year period, in equal installments, commencing on March 10, 2021, subject to the reporting person's continued service with the Issuer.
    /s/ Thomas John Freeburg 03/12/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IDXG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDXG

    DatePrice TargetRatingAnalyst
    11/17/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $IDXG
    SEC Filings

    View All

    Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

    8/8/25 4:28:44 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Interpace Biosciences, Inc.

    10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

    8/7/25 4:30:40 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Interpace Biosciences, Inc.

    10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

    5/8/25 4:28:33 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting

    Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAsLarge real-world analysis (n=28,144) demonstrates how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative casesPresentations were held during the ATA Annual Meeting, September 10–14, 2025, at the Westin Kierland in Scottsdale, Arizona PARSIPPANY, NJ, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) presented two new scientific pos

    9/15/25 9:15:00 AM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results

     ●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update. Second quarter Net Revenue was $9.2 million. Loss from continuing operations in the second quarter of 2025 was $0.5 million. "The Company achieved record Thyroid test volume, revenue, cash collections in the second quarter of 2025 driven by increased vo

    8/7/25 4:05:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

     ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million    PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter

    5/8/25 4:05:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Interpace Biosciences downgraded by HC Wainwright & Co.

    HC Wainwright & Co. downgraded Interpace Biosciences from Buy to Neutral

    11/17/21 6:16:49 AM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Interpace Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Interpace Biosciences with a rating of Buy and set a new price target of $9.00 from $6.00 previously

    4/9/21 7:22:39 AM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    HC Wainwright resumed coverage on Interpace Biosciences with a new price target

    HC Wainwright resumed coverage of Interpace Biosciences with a rating of Buy and set a new price target of $6.00 from $10.00 previously

    1/25/21 8:06:42 AM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccarthy Christopher converted options into 38,475 shares, increasing direct ownership by 463% to 46,791 units (SEC Form 4)

    4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

    4/25/25 4:18:01 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner 1315 Capital Ii, L.P.

    4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

    10/15/24 7:00:31 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Ampersand 2018 Limited Partnership

    4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

    10/15/24 7:00:05 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

     ●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year  ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million  PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. "2021 has been a transformative year for Interpace," said Thomas Burnell, President and CEO. Burnell added, "The Company e

    3/31/22 4:15:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

    PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in

    1/27/22 4:05:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Financials

    Live finance-specific insights

    View All

    Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

     ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper

    5/16/22 4:15:00 PM ET
    $IDXG
    $TWST
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

     ●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace

    11/10/21 4:05:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results

     ●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter  ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin

    8/10/21 4:05:00 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    $IDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

    SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

    10/16/24 4:35:44 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

    SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

    10/16/24 4:30:56 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Interpace Biosciences, Inc. (Amendment)

    SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

    2/12/24 5:01:48 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care